Compare VENUS REMEDIES with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES FRESENIUS KABI ONCO. VENUS REMEDIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -1.5 22.1 - View Chart
P/BV x 0.1 3.1 3.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
FRESENIUS KABI ONCO.
Mar-13
VENUS REMEDIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs126176 71.5%   
Low Rs6179 77.8%   
Sales per share (Unadj.) Rs301.837.7 800.8%  
Earnings per share (Unadj.) Rs-24.95.1 -488.3%  
Cash flow per share (Unadj.) Rs2.56.7 37.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.342.5 689.4%  
Shares outstanding (eoy) m12.34158.23 7.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.2%   
Avg P/E ratio x-3.825.0 -15.0%  
P/CF ratio (eoy) x36.718.9 194.1%  
Price / Book Value ratio x0.33.0 10.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15420,135 5.7%   
No. of employees `0000.91.2 80.3%   
Total wages/salary Rs m393703 55.9%   
Avg. sales/employee Rs Th4,026.15,176.2 77.8%   
Avg. wages/employee Rs Th425.0610.4 69.6%   
Avg. net profit/employee Rs Th-331.8699.6 -47.4%   
INCOME DATA
Net Sales Rs m3,7245,963 62.5%  
Other income Rs m2318 125.0%   
Total revenues Rs m3,7475,981 62.6%   
Gross profit Rs m3951,430 27.6%  
Depreciation Rs m338258 131.2%   
Interest Rs m354-26 -1,362.7%   
Profit before tax Rs m-2751,216 -22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m32342 9.2%   
Profit after tax Rs m-307806 -38.1%  
Gross profit margin %10.624.0 44.2%  
Effective tax rate %-11.528.1 -40.8%   
Net profit margin %-8.213.5 -61.0%  
BALANCE SHEET DATA
Current assets Rs m2,6385,102 51.7%   
Current liabilities Rs m2,3052,385 96.6%   
Net working cap to sales %8.945.6 19.6%  
Current ratio x1.12.1 53.5%  
Inventory Days Days135150 90.3%  
Debtors Days Days46113 40.9%  
Net fixed assets Rs m4,8715,148 94.6%   
Share capital Rs m123158 78.0%   
"Free" reserves Rs m3,4966,556 53.3%   
Net worth Rs m3,6196,732 53.8%   
Long term debt Rs m1,374952 144.3%   
Total assets Rs m7,50910,388 72.3%  
Interest coverage x0.2-45.8 -0.5%   
Debt to equity ratio x0.40.1 268.5%  
Sales to assets ratio x0.50.6 86.4%   
Return on assets %0.67.5 8.4%  
Return on equity %-8.512.0 -70.8%  
Return on capital %1.614.6 10.8%  
Exports to sales %074.5 0.0%   
Imports to sales %13.924.8 56.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs m5171,477 35.0%   
Fx inflow Rs m05,298 0.0%   
Fx outflow Rs m5171,772 29.1%   
Net fx Rs m-5173,525 -14.7%   
CASH FLOW
From Operations Rs m5141,274 40.4%  
From Investments Rs m-123-1,204 10.2%  
From Financial Activity Rs m-387-196 197.4%  
Net Cashflow Rs m4-126 -3.3%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.2 0.3 60.0%  
FIIs % 0.6 9.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 9.1 729.7%  
Shareholders   20,121 42,599 47.2%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALKEM LABORATORIES  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS